SASHA LATYPOVA on UNITED HEALTHCARE CEO BRIAN THOMPSON'S MURDER: My speculation on this is he was either going to testify or was compelled to testify as part of this, and it was going to bring down some very powerful individuals who are behind his company

(2/6) In May of this year, UnitedHealthcare Group CEO Andrew Witty testified before Congress regarding the ransomeware attack. Change Healthcare, the hacked division of UNH, processes $1.5 TRILLION in medical claims annually.

Witty—the CEO of the company that had revenues of… pic.twitter.com/700HrmbbCP

— Sense Receptor (@SenseReceptor) December 6, 2024

"My speculation on [UnitedHealthcare CEO Brian Thompson's murder] is he was either going to testify or was compelled to testify as part of [an ongoing DOJ investigation], and it was going to bring down some very powerful individuals who are behind his company." (1/6) Retired pharma R&D executive Sasha Latypova (@sasha_latypova) speculates on a recent episode of The Shannon Joy Show (

@ShannonJoyRadio

) as to the real reason UnitedHealthcare CEO Brian Thompson was recently murdered. Highlighting a gargantuan ransomware attack that targeted the health insurance and benefits corporation—which is a subsidiary of UnitedHealthcare Group—earlier this year, Latypova notes that "there's ongoing...litigation about that," which has already cost the company "several billion dollars"—not including whatever forthcoming settlement there may be. "[Thompson's] the CEO of the company that processes most of the Medicare and Medicaid claims, all kinds of insurance claims, in the United States," Latypova notes. "About a year ago, there was a breach of data. They got hijacked, ransomware. They had to pay a ransomware bribe and that also went sideways. There was a data breach exposed, about a hundred million Americans [had] their healthcare data, their Social Security numbers [exposed]. And so there's litigation ongoing about that. They already spent several billion dollars on that litigation, and that's before even the settlement." Latypova goes on to say that UnitedHealthcare is "also under investigation by the Department of Justice, which [is] also looking into all of this. And so [Thompson] was meeting with the investors, walked out in the morning, and then was gunned down right after that." The pharma insider adds, "My speculation on this is he was either going to testify or was compelled to testify as part of this, and it was going to bring down some very powerful individuals who are behind his company."

"Because it's such a huge company, such huge data that they're processing, they have to be connected to the same cabal...that's running this whole global thing," Latypova adds, referencing the ongoing global COVID operation (my term). 

LATYPOVA: ‘We can now have a non-investigational substance and use it in [a] non-medical and non-investigational way… That makes it [an] illicit drug.”

“Now we have this evolution, from expanded access use… where they said, ‘We can now have a non-investigational substance and use it in [a] non-medical and non-investigational way… That makes it [an] illicit drug.”

In this clip from the same interview, Latypova describes how,… pic.twitter.com/kfdvDon6wL

— Sense Receptor (@SenseReceptor) December 6, 2023

LATYPOVA:

“[W]hen you switch the status [of a regulatory pathway for a drug with the FDA]… to the non-investigational one [the EUA countermeasure pathway], the clinical trial becomes not a clinical trial—it’s just a collection of people trying drugs. Just like a recreational party…”

LATYPOVA:

The “first time the emergency use authorized thing came in was November 2003 through the National Defense Authorization Act, not through a bill that had to do with the FDA, or NIH, or public health, or anything like that.”

LATYPOVA:

The FDA lawyers said, in effect, “We want to violate the law, and we can’t, unless we design this new, extrajudicial pathway for ourselves.”